Compare SPOK & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | ALEC |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 262.7M |
| IPO Year | 2004 | 2019 |
| Metric | SPOK | ALEC |
|---|---|---|
| Price | $11.14 | $2.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $4.83 |
| AVG Volume (30 Days) | 158.7K | ★ 709.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | ★ 2.74 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $139,708,000.00 | $21,045,000.00 |
| Revenue This Year | $1.70 | $18.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.80 | ★ N/A |
| Revenue Growth | ★ 1.49 | N/A |
| 52 Week Low | $10.81 | $0.87 |
| 52 Week High | $19.31 | $3.40 |
| Indicator | SPOK | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 60.70 |
| Support Level | N/A | $1.89 |
| Resistance Level | $13.87 | $2.55 |
| Average True Range (ATR) | 0.26 | 0.19 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 52.31 | 73.72 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.